Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 14/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 2/20 | 0.34 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572235 | 0.84 | PTGDR2 (0.54) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL27780421 | 0.84 | PTGDR2 (0.41) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL27893548 | 0.83 | PTGDR2 (0.42) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL2574623 | 0.81 | PTGDR2 (0.46) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL2570635 | 0.80 | RORC (0.37) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL2572952 | 0.79 | PTGDR2 (0.40) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL2573093 | 0.77 | SCN9A (0.38) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL2573604 | 0.76 | PTGDR2 (0.66) | PTGDR2RORCCCNE1CDK2USP1 | |
| SCHEMBL3778570 | 0.75 | ENPP2 (0.34) | RORC | |
| SCHEMBL2582465 | 0.74 | PTGDR2 (0.48) | PTGDR2RORCCCNE1CDK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394830-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-2139881-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2139881-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Oral Therapeutics Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122784-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | PTGDR2 301/4885RORC 111/4885CCNE1 1017/4885 |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | HRH1, CHRM2, CHRM3 | PTGDR2 316/4885RORC 118/4885CCNE1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.